FN1 and neoplasm: To this purpose several antibodies derived from phage display, targeting tumor overexpressed cytokines (e.g., GC-1008, an anti-Transforming Growth Factor β cytokine [152]), tumor stromal antigens (e.g., L19, an anti-isoform B of fibronectin [153]), or tumor-associated antigens (e.g., adecatumumab, that recognize epithelial cell-adhesion molecules [154]) are currently in clinical trials.